← Back to Screener
FibroBiologics, Inc. Common Stock (FBLG)
Price$1.52
Favorite Metrics
Price vs S&P 500 (26W)-88.75%
Price vs S&P 500 (4W)-76.26%
Market Capitalization$5.41M
All Metrics
Book Value / Share (Quarterly)$0.09
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.25
Price vs S&P 500 (YTD)-68.42%
EPS (TTM)$-0.44
10-Day Avg Trading Volume0.76M
EPS Excl Extra (TTM)$-0.44
EPS (Annual)$-0.42
ROI (Annual)-302.89%
Cash / Share (Quarterly)$0.07
ROA (Last FY)-193.85%
EBITD / Share (TTM)$-0.38
Cash Flow / Share (Annual)$-0.25
P/B Ratio0.88x
P/B Ratio (Quarterly)2.43x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-12.53x
ROA (TTM)-170.69%
EPS Incl Extra (Annual)$-0.42
Current Ratio (Annual)3.61x
Quick Ratio (Quarterly)2.78x
3-Month Avg Trading Volume0.26M
52-Week Price Return-92.14%
Revenue / Employee (TTM)$0
52-Week High$30.60
EPS Excl Extra (Annual)$-0.42
26-Week Price Return-84.77%
Quick Ratio (Annual)2.78x
13-Week Price Return-80.03%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)3.61x
Enterprise Value$0.516
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.07
3-Month Return Std Dev166.81%
Net Income / Employee (TTM)$-1
ROE (Last FY)-302.89%
Net Interest Coverage (Annual)-6.62x
EPS Basic Excl Extra (Annual)$-0.42
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.44
ROI (TTM)-266.67%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-121.97%
Year-to-Date Return-65.78%
5-Day Price Return11.59%
EPS Normalized (Annual)$-0.42
ROA (5Y Avg)-169.07%
Month-to-Date Return16.67%
EBITD / Share (Annual)$-0.38
EPS Basic Excl Extra (TTM)$-0.44
P/B Ratio (Annual)2.43x
Book Value / Share (Annual)$0.09
Price vs S&P 500 (13W)-80.71%
Beta-0.64x
Revenue / Share (TTM)$0.00
ROE (TTM)-785.84%
52-Week Low$1.03
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.11
4.11
4.11
4.00
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
FBLGFibroBiologics, Inc. Common Stock | — | — | — | — | $1.52 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
FibroBiologics Inc is a clinical-stage biotechnology company developing fibroblast-based therapies for chronic diseases with unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, and psoriasis. The company's pipeline comprises four candidates: CYWC628, CYPS317, CYMS101, and CybroCell, with additional exploration in oncology and age-related conditions, including novel approaches to reverse thymic involution.